



## Report of Voting Results Medicenna Therapeutics Corp.

In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual and special meeting of shareholders of Medicenna Therapeutics Corp. (the "Corporation") held on September 21, 2017 in Toronto, Ontario.

1. By a resolution passed by a majority of the votes cast by a show of hands (of which approximately 99.95% of the votes represented by proxy voted in favour and approximately 0.05% of the votes represented by proxy voted against), the number of directors was fixed at 6.
2. By a resolution passed by a majority of the votes cast by a show of hands, each of the following directors were elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed:

<b>Nominee</b>	<b>Votes For</b>	<b>% Votes For</b>	<b>Votes Withheld</b>	<b>% Votes Withheld</b>
Dr. Fahar Merchant	18,445,853	99.92%	14,000	0.08%
Dr. Chandrakant Panchal	18,445,853	99.92%	14,000	0.08%
Mr. Albert Beraldo	18,445,853	99.92%	14,000	0.08%
Ms. Rosemina Merchant	18,454,853	99.97%	5,000	0.03%
Mr. Andrew Strong	18,445,853	99.92%	14,000	0.08%
Dr. William W. Li	18,445,853	99.92%	14,000	0.08%

3. By a resolution passed by a majority of the votes cast by a show of hands (of which approximately 99.92% of the votes represented by proxy voted in favour and approximately 0.08% of the votes represented by proxy withheld from voting), Davidson & Company LLP was re-appointed as auditor of the Corporation to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration.
4. By a resolution passed by a majority of the votes cast by a show of hands (of which approximately 94.93% of the votes represented by proxy voted in favour and approximately 5.07% of the votes represented by proxy voted against), the 2017 stock option plan was passed as proposed.

In total, approximately 75.83% of the issued and outstanding shares were represented in person or by proxy at the meeting.

Yours very truly,

/s/ Elizabeth Williams

Elizabeth Williams  
Chief Financial Officer